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ABSTRACT 
The aim of this study was to evaluate the outcomes of combined endocyclophotocoagulation (ECP) and 
phacoemulsification regarding vision, refraction, intraocular pressure (IOP), medication dependence, and complications 
in patients of African descent. A retrospective chart review was performed including all cases of ECP combined with 
phacoemulsification from October 2015 to March 2017. Exclusion criteria consisted of patients who were not of African 
descent and patients with <1 month follow-up. IOP was the primary outcome. Thirty-two eyes of 29 patients were 
included in the study. Mean ± standard deviation (SD) of IOP decreased from 17.30 ± 6.30 mmHg preoperatively to 15.88 
± 4.23 mmHg at the last postoperative visit (P = 0.301). In 2 of eight patients who did not demonstrate a difference in 
pre- and postoperative IOP changes, all IOP lowering medications were stopped. The mean ± SD of follow-up was 5.05 ± 
4.08 months with a range of 1 to 18 months. The mean ± SD number of medications used for each patient for IOP control 
decreased from 2.59 ± 1.01 preoperatively to 1.97 ±1.38 (P = 0.045). Average visual acuity improved from 20/50 
preoperatively to 20/25 (P = 0.002). Postoperative complication rate was low. ECP combined with phacoemulsification 
was effective to decrease IOP lowering medication dependence in patients of African descent. We found that combined 
ECP and phacoemulsification can lead to a significantly decreased dependence on IOP lowering drops, with some 
patients demonstrating complete independence from drops following surgery. Although there was not a significant 
decrease in IOP postoperatively when analyzed collectively, larger studies might to find such an association. Combined 
ECP and phacoemulsification has been shown to be a safe combination in patients with refractive glaucoma and may be 
considered if a patient desire less dependence on IOP lowering drops once other first-line methods have failed, or as a 
bridge between conservative and more definitive surgical treatment. 
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INTRODUCTION
Minimally invasive glaucoma surgeries (MIGS) have risen 
in popularity in the recent years due to a higher safety 
profile than traditional, invasive glaucoma surgeries such 
as trabeculectomies or glaucoma drainage devices [1, 2]. 
Endocyclophotocoagulation (ECP) is a MIGS option used 
since 1980s and has commonly been reserved for 
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refractory or end-stage glaucoma [3]. In such cases, all 
other treatment options including maximal medical 
therapy, laser and surgical intervention have already 
been used yet the patient’s glaucoma continues to 
progress or intraocular pressure (IOP) continues to 
remain above the acceptable standards. ECP involves the 
use of an endoscopic probe with a camera and diode 
laser to ablate the ciliary body. This results in decreased 
aqueous production and subsequently a lower IOP [4]. 
ECP has been shown to be successful as both a stand-
alone procedure or in combination with cataract surgery 
[5]. Several studies have been published to assess the 
outcomes of ECP in advanced and refractory glaucomas 
including a prospective trial by Lima et al. [6] which 
compared ECP to the Ahmed glaucoma valve (AGV) in 
refractory glaucomas that have already undergone at 
least one prior trabeculectomy; they found no difference 
in the success rate between AGV and ECP. In fact, they 
found more complications by using AGV compared to the 
ECP. In another study, Kahook et al. [7] compared ECP 
treatment at one site versus two sites, evaluating the 
effect that extended treatment would have on IOP 
lowering. ECP has been reviewed in pediatric patients 
and also in studies looking for refractive outcomes [8, 9]. 
Recently, Smith et al. studied the effects of combined 
phacoemulsification and 360 degree ECP over 3 years in 
84 patients with uncontrolled glaucoma and no prior 
history of glaucoma surgery. They found that 58.3% of 
cases had met failure criteria at the end of 3 years [10]. 
Despite the literature on ECP, there has only been one 
study comparing ECP outcomes in patients of African 
descent [11]. Given that refractory glaucoma is very 
common in this population compared to other 
populations, additional treatment options in these 
patients might be useful [12]. 
This retrospective study aimed to evaluate the outcomes 
of one-site ECP combined with cataract surgery for 
vision, IOP, refractive error and IOP lowering medication 
dependence to evaluate its effectiveness as an additional 
treatment option for patients of African descent. 
METHODS 
The study followed the tenets of the Declaration of 
Helsinki, met local Ethical Clearance and was approved 
by the institutional review board (IRB) of Boston Medical 
Center. A retrospective chart review was performed of all 
cases of ECP (Beaver Visitek® Endo Optiks®, Waltham, 
MA, USA) combined with phacoemulsification cataract 
surgery via the Centurion® (Alcon, Fort Worth, TX) at 
Boston Medical Center from October 2015 to March 
2017. Demographic data including age, race and gender 
were collected (Tables 1 and 2). Preoperative ocular 
parameters included glaucoma type and stage, previous 
surgeries, corrected distance visual acuity (CDVA), IOP, 
number of glaucoma medications used and surgical 
refractive target. Postoperative measures included CDVA, 
refraction, IOP (Table 1) and surgical complications. 
Glaucoma was staged according to the consolidated 
staging scheme developed by Ng et al. [13]. All types and 
stages of glaucoma were included in this study. Exclusion 
criteria included patients who were not of African 
descent and those who were lost to follow-up prior to 
one month. A paired t-test was used for statistical 
analysis of visual acuity, number of IOP lowering 
medications the patient remained dependent on and IOP 
at the latest visit. 
 
Table 1: Demographics and Ocular Parameters 
  P- value 
Mean Age (Y) 68.4  
Total eyes (n) 32  
Gender   
Female (n) 20  
Male (n) 9  
Pre-op CDVA, (logMAR) 0.403 ± 0.454  
Post-op CDVA, (logMAR) 0.114 ± 0.226 0.004 
Number of Glaucoma Medications pre-
op (Mean ± SD) 
2.59 ± 1.01  
Number of Glaucoma Medications in 
last visit (Mean ± SD) 
1.97 ± 1.38 0.004 
Pre-op IOP (Mean ± SD) 17.30 ± 6.30  
Post-op IOP, at last visit (Mean ± SD) 15.88 ± 4.23  
Glaucoma Type  0.130 
Advanced POAG, n (%) 10/32 (31)  
Moderate POAG, n (%) 7/32 (22)  
Mild POAG, n (%) 3/32 (9.4)  
Indeterminate POAG*, n (%) 2/32 (6)  
Advanced CACG, n (%) 7/32 (22)  
Advanced Uveitic glaucoma, n (%) 1/32 (3)  
Moderate Pigment Dispersion 
Glaucoma, n (%) 
1/32 (3)  
Ocular Hypertension, n (%) 1/32 (3)  
Previous Interventions   
SLT, n (%) 10/32 (31)  
LPI, n (%) 7/32 (22)  
Trabeculectomy, n (%) 2/32 (6)  
Ahmed glaucoma valve, n (%) 4/32 (12.5)  
PRP, n (%) 1/32 (3)  
Pars Plana Vitrectomy, n (%) 1/32 (3)  
Abbreviations: Y: year; n: number; CDVA: corrected distance visual acuity; F; 
female; M; male; SD: standard deviation; logMAR: Logarithm of the Minimum 
Angle of Resolution; IOP: intraocular pressure; %: percentage; POAG: primary 
open angle glaucoma; CACG: chronic angle closure glaucoma; SLT: selective laser 
trabeculoplasty; LPI: Laser Peripheral Iridotomy; PRP: Panretinal 
Photocoagulation: Pre-op: preoperative; Post-op: post operative. P<0.05 has 
been bold. 
 
IOP pressure was measured using the Goldmann 
applanation (Haag-Streit Diagnostics, Bern, Switzerland) 
by a physician on 1 day, 1 week and 1 month following 
surgery for all patients. If patients were followed 
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between the above listed visits or for longer than 1 
month, the IOP at each visit and the latest IOP were 
recorded as well. Corrected distance visual acuity with 
Snellen chart and manifest refraction were completed at 
least 1-month postoperatively. Residual refractive 
outcomes were also evaluated by determining the 
difference between the spherical equivalent of the 
refractive goal and the postoperative manifest refraction. 
Statistical analysis was performed using Student’s 2-
tailed T test on GraphPad Prism 6.0 (GraphPad Software 
Inc., San Diego, CA, USA). 
 
Table 2: Ethnicity in Combined Endocyclophotocoagulation and 
Phacoemulsification in Patients with Glaucoma  
Outcome Measures 
The primary outcome measured was IOP at the last visit. 
Secondary outcomes included CDVA at least 1 month 
after surgery, refractive outcomes, number of glaucoma 
medications and complications. 
Complete success was defined as an IOP lowering of ≥ 
20% from the preoperative amount while the patient 
remained off all glaucoma medications. Also, qualified 
success was defined as an IOP lowering of ≥ 20% while 
remaining on glaucoma medication(s). 
Surgical Method 
After phacoemulsification with intraocular lens (IOL) 
placement in the lens bag, the sulcus was inflated with 
viscoelastic (Provisc®, Alcon Ft. Worth, TX, The USA). A 
19-gauge ECP (Beaver Visitek® Endo Optiks®, Waltham, 
MA, USA) probe was then inserted into the main wound 
and the camera was focused on the ciliary body 
processes with an optimal view of 4-6 ciliary processes at 
a time (Figure 1). A power of 0.20-0.25 milliwatt (mw) on 
a continuous setting was used to treat 4-6 clock hours 
(120 to 180 degrees) of ciliary body processes. The 
viscoelastic was then removed via the irrigation and 
aspiration handpiece and the wounds were sealed with 
balanced with salt solution. 
Postoperative Regimen and Follow-up 
The postoperative regimen included subconjunctival 
injection of cefazolin and dexamethasone and topical 
prednisolone acetate 1% (Allergan, Madison, NJ, The 
USA) 6 times per day tapered over 6 weeks, a fourth 
generation fluoroquinolone (Vigamox, Alcon, Ft. Worth, 
TX, The USA) 4 times a day for 1 week and ketorolac 0.5% 
(Allergan, Madison, NJ, The USA) 4 times a day for 1 
month to the operated eye. Prostaglandin analogs were 
stopped immediately postoperatively; however, all other 
glaucoma medications were continued in the immediate 
postoperative period at day 0. The patient was followed 
at day 1, week 1 and month 1 and then as directed by the 
surgeon based on IOP and inflammation. IOP medications 
were then either added or subtracted at each 
subsequent visit at the surgeon’s discretion. 
 
Figure 1: Intraoperative View of Ciliary Processes after Laser Ablation 
Following Endocyclophotocoagulation (ECP). 
 
RESULTS 
Demographics and Ocular Parameters 
Thirty-two eyes of 29 patients were included in the 
study. Twenty females and 9 males were included with a 
mean ± standard deviation (SD) age of 68.4 ±8.6 years 
(Table 1). Most patients were either of African American 
or Haitian decent but patients of Jamaican, Cape 
Verdean, Moroccan and Trinidadian descent were also 
included (Table 2). 
 
Table 3: Mean Intraocular Pressure at Different Time Points in 
Combined Endocyclophotocoagulation and Phacoemulsification in 
Patients with Glaucoma of African Descent 
Time Period IOP Number of eyes 
Day 1 21.4 ± 8.0 32 
Week 1 17.3 ± 4.9 32 
Month 1 17.7 ± 4.5 32 
IOP Last   
1-3 Months 16.4 ± 2.0 13 
4-6 Months 15.1 ± 3.8 12 
7-10 Months 14.7 ± 2.3 3 
11-18 Months 19.5 ± 3.9 4 
*IOP measured in millimeter of mercury (mmHg) 
Data in table are presented as Mean ± SD (Standatd Deviation) 
Ethnicity Number of eyes 
(Percentage) 
African American  12 (41) 
Haitian 11 (38) 
Jamaican 2 (6) 
Cape Verdean 2 (6) 
Trinidadian 1 (3) 
Moroccan 1 (3) 
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Ten of 32 (31%) eyes had advanced primary open angle 
glaucoma (POAG), 7 (22%) had moderate POAG, 3 (9%) 
mild POAG and 2 (6%) an indeterminate stage of POAG. 
Seven of 32 (22%) had advanced chronic angle closure 
glaucoma (CACG). There was one patient each with 
ocular hypertension, uveitic glaucoma and pigment 
dispersion glaucoma. Previous laser intervention and 
surgical treatment are represented in Table 1. 
IOP and Medications 
The pre- and postoperative IOP and number of glaucoma 
medications used pre- and postoperatively are listed in 
Tables 1 and 3. The mean ± SD of preoperative IOP was 
17.3 ± 6.3 mmHg. The postop IOP was reviewed for each 
patient on postoperative day 1, week 1 and month 1 as 
well as on the latest visit after one-month postoperative 
period. The mean ± SD of patient follow-up was 5.05 ± 
4.08 months with a range of 1 to 18 months. At day 1, 
the mean ± SD of IOP was 21.4 ± 8.0 mmHg, at week one 
17.3 ±4.9 mmHg and at month one 17.7 ± 4.5 mmHg. 
Thirteen eyes followed up 3 months after surgery and 
the mean ± SD of IOP for this time frame was 16.4 ± 2.0 
mmHg. Twelve eyes completed the follow-up between 4 
and 6 months after surgery and the mean ± SD of IOP 
was 15.1 ± 3.8 mmHg. Three eyes had follow-up between 
7 and 10 months and the mean ± SD of IOP in this group 
was 14.7 ±2.3 mmHg. Four eyes had follow-up between 
11 and 18 months after surgery and the mean ± SD of IOP 
was 19.5 ±3.9 mmHg (Table 3, Figure 2). The mean ± SD 
of IOP at the last visit for all patients without considering 
length of follow-up after one month postoperatively was 
15.88 ±4.23 mmHg compared to 17.3 ±6.30 mmHg 
preoperatively (p = 0.130). This represented an 8.2% 
drop in IOP compared to before surgery. Two of 32 
patients (6%) achieved complete success while 9 (28%) 
achieved a qualified success. Also, 6 patients (67%) in the 
qualified success group were able to achieve an IOP 
lowering of >30% and two patients an IOP lowering of 
>40%. Eight of 32 patients (25%) ended up with higher 
IOPs than their preoperative measures. Additionally, 7 
(22%) experienced no change in IOP compared to their 
preoperative measures. However, 2 of these 7 patients 
were able to be weaned off of their IOP lowering 
medications completely. In the qualified success group, 
6/9 (66%) had moderate to advanced POAG. Of the 8 
that worsened, 6 had POAG and the other 2 had CACG. 
 Preoperatively, the mean ± SD of number of glaucoma 
medications was 2.59 ±1.01. At last visit after surgery, 
the mean ± SD of number of glaucoma medications was 
1.97 ±4.23 showing a 24% reduction (P = 0.004). 
 
 
Figure 2: Intraocular Pressure (IOP) in Millimeters of Mercury (mmHg) over Time 
 
Visual Acuity and Refractive Outcomes 
The mean± SD of CDVA in logMAR were 0.57±0.68 and 
0.15±0.26 preoperatively and at last visit postoperatively, 
respectively (p = 0.002) as shown in Table 1. Refractive 
outcomes were also evaluated by comparing 
postoperative spherical equivalent to the spherical 
equivalent of the refractive goal based on the IOL 
calculations obtained preoperatively. A target refraction 
within 1.0 diopters (D) of the refractive target was 
considered meeting the patient’s refractive goal as 
described by Simon et al. [14]. Twenty-seven of 32 eyes 
met the refractive goal. However, 5 of 32 eyes (16%) 
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were >1.0D away from their goal, whereby 3 of these 
eyes experiencing a myopic surprise and 2 a hyperopic 
surprise. Additionally, 14 of 32 eyes (44%) were found to 
be > ± 0.50D of goal with 10 of these eyes ending up 
more myopic and 6 of these eyes ending up more 
hyperopic. Overall, 18 of 32 eyes (56%) were found to be 
within ± 0.50D of goal (Table 4). 
Complications 
Complications were noted as early (less than 1 month 
after surgery) or late (greater than 1 month after 
surgery) and occurred in 14 of 32 eyes (Table 5). The 
most common complication was an IOP spike defined as 
an increase in IOP of > 10mmHg from baseline on 
postoperative day 1 (POD 1) which occurred in 8 of 32 
eyes (25%). These patients were treated with topical IOP 
lowering medications and IOP was stabilized prior to the 
patient leaving clinic. Cystoid macular edema (CME) 
occurred in 2 of 32 eyes (6%). Prolonged postoperative 
inflammation occurred in 1 of 32 eyes (3%) but resolved 
with topical steroids. One patient developed a hyphema 
on POD 1 which resolved by the following week. Another 
patient developed a steroid response that required an 
additional Baerveldt glaucoma implant to adequately 
control the IOP. 
 
Table 4: Refractive Outcomes of Combined 
Endocyclophotocoagulation and Phacoemulsification in Patients with 
Glaucoma of African Descent 
Outcome n (%) Mean ± SD 
>±1.0 D of goal 5/32 (16)  
Myopic surprise 3/5 -1.12 ± 0.15 
Hyperopic surprise 2/5 +1.27 ± 0.14 
>±0.50 D of goal 14/32 (44)  
Myopic deviation 8 -0.78 ± 0.25 
Hyperopic deviation 6 +0.91 ± 0.30 
Within ± 0.50D of Goal 18/32 (56) +0.02 ± 0.30 
Abbreviations: D: diopter; SD: standard deviation; %: percentage; n: number of 
eyes. 
 
Table 5: Complications Combined Endocyclophotocoagulation and 
Phacoemulsification in Patients with Glaucoma of African Descent 
Early Complications (< 1 month) n (%) 
Postoperative day 1 IOP Spike 8/32 (25) 
Post-operative Iritis 1/32 (3) 
Hyphema 1/32 (3) 
Late Complications (> 1 month)  
Cystoid Macular Edema 2/32 (6) 
Steroid Response 1/32 (3) 
Further Surgery (Baerveldt glaucoma implant) 1/32 (3) 
Abbreviations: IOP: Intraocular pressure; SD: standard deviation; mmHg: 
millimeters of Mercury ; %: percentage; n: number.  
 
 
 
 
DISCUSSION 
Our study aimed to look at ECP combined with 
phacoemulsification outcomes specifically in patients of 
African descent with varied types and stages of 
glaucoma. We demonstrated that ECP combined with 
phacoemulsification can be effective to decrease IOP 
and/or lowering medication dependence in patients of 
African descent. We also found that combined ECP and 
phacoemulsification is safe with no vision threatening 
complications. The most common complication was 
elevated IOP on postop day 1 visit (8 of 32 patients, 
25%).ECP has been used since the 1980s for the 
treatment of many types of glaucoma [3]. Francis et al. 
[15] showed that ECP combined with 
phacoemulsification was more effective than cataract 
extraction alone to lower IOP and decrease IOP lowering 
medication dependence specifically in eyes with mild to 
moderate glaucoma previously controlled with IOP 
lowering medications. However, a recent study by Smith 
et al. indicated that these results are temporary [10]. 
Lima et al. [6] in a prospective study comparing ECP to 
AGV in patients with refractory glaucoma who were 
pseudophakic and had undergone trabeculectomy with 
antimetabolite previously, demonstrated that IOP 
lowering was similar between the two groups and the 
ECP group had less complications comparted to the AGV 
group. Another prospective study by Gayton et al. [16] 
comparing ECP combined with phacoemulsification to 
phacoemulsification alone in patients with prior 
trabeculectomy found comparable IOP lowing results and 
decreased IOP lowering medication dependence. A 
retrospective review by Chen et al. also found that ECP is 
safe and effective in refractory glaucomas of various 
types, including in patients who have had previous 
trabeculectomy or tube shunts [17]. Recently, Murakami 
et al. noted that ECP functions equivalently to a second 
glaucoma drainage device in eyes that have had a prior 
implanted drainage device [18]. ECP has even been 
studied in difficult pediatric glaucoma including 
congenital glaucoma, aphakia, Sturge-Weber syndrome 
and aniridia [8, 19]. Despite the limited but varied data 
regarding ECP, only one previous study has looked 
specifically at results of ECP in a population of patients of 
African descent. This study found that postoperative 
inflammation is higher in patients of African descent but 
did not find any differences in IOP or best corrected 
visual acuity (BCVA) compared to patients of Caucasian 
decent [11]. Studying the effects of combined ECP 
procedures in patients of African descent is important 
since refractory glaucoma is very common amongst these 
individuals despite maximal medical therapy and surgical 
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interventions, thus rendering further options necessary 
[11, 20]. 
In our retrospective study, it appears that four patients 
received a robust IOP lowering of up to 40%. Specifically, 
a patient with severe stage CACG post-trabeculectomy 
had a 42% reduction, another patient with severe stage 
POAG post-AGV demonstrated a 42% reduction, a 
patient with severe stage POAG post selective laser 
trabeculoplasty (SLT) had a 38% reduction and a patient 
with moderate POAG with no prior intervention showed 
a 38% reduction. However, some patients did not 
respond to combined phacoemulsification and ECP. 
When analyzing subsets of our population, 3 patients 
who had undergone either a prior trabeculectomy or 
AGV achieved a significant IOP lowering. Combined ECP 
and phacoemulsification may be quite effective in these 
particular patients, which is consistent with results of 
some prior studies [6, 17]. Combined ECP and 
phacoemulsification was successful in 6 of 9 (67%) 
patients who had POAG. In seven of thirty eyes (22%) IOP 
worsened following the procedure. Of these seven eyes, 
four of them were receiving fewer IOP lowering drops 
postoperatively than preoperatively. Latanoprost or an 
equivalent prostaglandin analog was stopped after 
surgery. Perhaps discontinuing IOP lowering medications 
postoperatively caused an increase in IOP. Additionally, 
2/7 (29%) patients who had a higher postoperative IOP 
developed CME. One patient with CME had POAG and 
another had CACG. Of the patients who demonstrated 
worsening IOP postoperatively, there was a mix of 
glaucoma status and types and none had undergone 
prior filtering or tube shunt surgeries. In our study, 4-6 
clock hours, or 120-180 degrees of ciliary processes were 
treated through a single incision. While a previous study 
by Uram [21]
 
found the efficacy of the same amount of 
treatment, a few others suggested a greater treatment 
area to achieve adequate IOP lowering. One such study 
by Patel et al. recommended treating an area of at least 
180 degrees while Zabrin et al. found treating 240 
degrees to be more effective [3, 22]. More recently, 
Kahook compared 1-site of 240 degree ECP treatment 
versus 2-site ECP treatment of 240-360 degrees and 
found that 2-site ECP combined with phacoemulsification 
resulted in a statistically significant lowering of IOP 
compared to 1-site ECP treatment. He also noted that 2-
site ECP treatment resulted in less IOP medication 
dependence. Besides, there was no difference in 
inflammation or complication rate in the 2-site group 
compared to the 1-site group. Our lower complication 
rate in comparison to other studies may be related to the 
relatively smaller degree of ciliary processes treated; 
however, larger treatment areas may be more effective 
and may have a similar safety profile compared to a 
smaller treatment area [7]. This may be a future area of 
comparison in patients of African descent. 
The complication rate was low with a POD 1 IOP spike 
being the most common complication. This IOP spike 
resolved in all patients with the use of topical IOP 
lowering medications in the office. After administration 
of oral Diamox 500mg postoperatively to all patients, no 
further POD 1 IOP spikes were noted. Only one patient 
required an AGV to further lowering IOP; however, this 
patient had a preoperative IOP of 48 mmHg and post-
ECP/phacoemulsification measure dropped to 28 mmHg. 
Combined ECP/phacoemulsification was attempted in 
this patient prior to an AGV since the patient requested a 
less invasive procedure prior to considering a drainage 
device. No patients developed severe complications such 
as hypotony, choroidal detachments or fibrin in the 
anterior chamber. As mentioned above our lower 
complication rate in comparison to other studies could 
be related to the relatively smaller degree of ciliary 
processes treated. Only one of 32 eyes (3%) developed a 
small hyphema which resolved without complication and 
one eye of another patient (3%) developed postoperative 
iritis which resolved with topical steroids. Both of these 
patients had POAG. In total, two of 32 eyes (6%) 
developed CME. Our complications rate is lower than 
that reported by Chen et al. [17]. For example, we had no 
cases of fibrin in the anterior chamber compared to 22% 
[17]. The hyphema rate (3%) was lower in our study 
compared to 12% reported by Chen et al. [17]. Our CME 
rate was 6% which is lower compared to 10% [17]. Our 
lower complication rate may be attributed to a smaller 
treatment area as noted previously. 
Postoperatively, 2 of 32 eyes (6%) achieved complete 
success with an IOP lowering of ≥ 20% without 
consuming any IOP lowering medications. Despite the 
low percentage of complete success, no other studies 
used this strict criterion for complete success in the 
setting of ECP. Both patients with complete success were 
of Haitian decent and had POAG. Qualified success, 
defined as IOP lowering of 20% from baseline at the last 
visit regardless of IOP lowering medication use was found 
in 9 of 32 eyes (28%). Similar criteria for qualified success 
have been used in other studies in the glaucoma 
literature [23, 24]. In the qualified success group 5 were 
of Haitian decent. Seven of 9 had moderate to advanced 
POAG, 1 advanced CACG and 1 ocular hypertension. 
Thus, considering the complete and qualified success 
groups as a whole, POAG and Haitian descent associated 
with significant IOP lowering postoperatively. Compared 
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to the literature, our complete and qualified success 
rates are lower than those found in a recent study by 
Clement et al. who used similar success criteria and 
found success in 55.5% of eyes at 12 months [24]. 
Perhaps this higher success rate was due to a larger area 
of treatment and shorter follow-up time. In our study, 
patients who were followed for greater than 12 months 
demonstrated a rise in IOP suggesting that the pressure 
lowering effect of ECP is only temporary. However, due 
to limited length of follow-up and only 4 of 29 patients 
completed a 12-month follow-up, it would be difficult to 
make that conclusion without a larger sample size. ECP 
results have been variable, with some studies showing 
continued IOP lowering success for up to 2-3 years [6, 10, 
25]. Perhaps our lower success rate over time could be 
attributed to our population which has a higher 
proportion of advanced and refractory glaucoma, and to 
our smaller ECP treatment zone. Overall, IOP was 
decreased on average by 5% from baseline and all 
patients were able to be weaned off of one IOP lowering 
medication averagely. Roberts et al. found that combined 
ECP and phacoemulsification resulted in lower IOPs at 
early stages, but IOP steadily increased throughout the 
12-month follow-up. This study stratified outcomes 
based on race but did not find any statistical difference 
amongst race. It noted that the only outcome associated 
with successful treatment was preoperative IOP [25]. Our 
results are similar to a recent review of ECP combined 
with phacoemulsification by Rathi and Radcliffe [26]. 
Although we did not find a statistically significant drop in 
IOP status post-treatment, we did find a statistically 
significant decreased dependence on IOP lowering 
medication following treatment. 
CDVA improved after surgery, the outcome was excellent 
with an average CDVA of logMAR 0.15 (Snellen acuity of 
20/28), including patients with limited visual potential 
due to advanced glaucoma or retinal pathology (i.e. 
epiretinal membrane). Furthermore 19/32 (59%) ended 
up with a CDVA of 20/20 (logMAR 0) and 28/32 (88%) 
achieved a BCVA of >20/30. Such visual acuity results is 
comparable to a study by Siegel et al. [27] which 
compared the outcome of ECP and phacoemulsification 
with phacoemulsification alone. This is the third 
investigation in the literature to our knowledge to assess 
refractive outcomes. In a retrospective case series, Wang 
et al. [28] compared refractive results of combined ECP 
and phacoemulsification to phacoemulsification alone. 
They found that in combined ECP, refractive outcomes 
were less predictable and patients often experienced a 
small myopic shift. Moreover, another retrospective case 
series by Kang et al. [8] found more refractive variability 
postoperatively in eyes who underwent ECP combined 
with phacoemulsification compared to those who 
underwent phacoemulsification alone. We found 84% of 
patients to be within ±1.00 D which is similar to Kang et 
al. finding of 90% to be within this goal. Furthermore, 
only 48% of patients with combined ECP were within 
±0.50D of goal, while 100% of phacoemulsification 
without ECP cases were within ±0.50 D of goal [9]. In our 
study, 5/32 (16%) were > ±1.0 D of goal. Of these 5 cases, 
3 resulted in a myopic surprise and 2 a hyperopic 
surprise. Four of 5 of these patients, 3 with POAG and 1 
with CACG, who obtained a refractive surprise had 
advanced glaucoma, suggesting that patients with 
advanced disease are more likely to experience a 
refractive surprise probably. Sixteen of 32 eyes (56%) 
ended up within ± 0.50 D of goal. These outcomes 
suggest that physicians should take extra care to adjust 
for IOL power. Currently no formula exists to adjust for 
ECP combined phacoemulsification refractive outcomes. 
The quality of each preoperative biometry, A-scan, and 
Keratometry readings were reviewed in our study and 
found to be accurate. One explanation for the variable 
refractive surprises may be that the lens/zonule complex 
is attached to the ciliary body, which is non-uniformly 
ablated during ECP. Moreover, ablating only a small 
section of ciliary bodies could result in shifts of the entire 
lens complex. Considering our study and the 2 prior 
studies, postoperative refractive surprises may be 
possible and patients need to be counseled accordingly. 
The strength of our study is the patient demographics. 
Our study population included subjects of African 
descent, as glaucoma is more common. Glaucoma is a 
leading cause of decreased vision and/or blindness in this 
population, hence it is important to analyze different 
surgical options such as ECP combined with 
phacoemulsification in this group. Additionally, we 
included all types and stages of glaucoma in our study, so 
that we could assess whether there is a certain subgroup 
in which ECP combined with phacoemulsification is more 
successful and safe. The limitations of our study were the 
small sample size, the design of the study (retrospective 
case series) and the short duration of study (mean 
follow-up of 5 months, with a range of 1-18 months). We 
suggest more studies with larger sample size, longer 
follow-up period and more valid study design to achieve 
more robust conclusion. 
CONCLUSIONS 
Combined phacoemulsification and ECP had a low 
complication rate and may serve as a helpful and safe 
procedure in the management of glaucoma. In particular, 
combined ECP/phacoemulsification may work better in 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2019; 8(4)  
264 ENDOCYCLOPHOTOCOAGULATION AND PHACOEMULSIFICATION IN PATIENTS WITH GLAUCOMA 
patients with POAG who have had prior glaucoma 
surgery when further surgical options are limited. Due to 
the variability in refractive outcomes after surgery, 
preoperative planning should be considered. Limitations 
include the retrospective nature of our study, short 
follow-up period with only 4/29 patients who followed 
up to 12 months, lack of a control group and a small 
sample size. In addition, a larger treatment area in 
addition to 4-6 clock hours might result in a higher 
success rate than what was reported. Overall, ECP 
combined with cataract surgery can achieve robust IOP 
lowering in some patients while achieving no 
improvement or even worsening IOP in some patients of 
African descent. In patients who did not show 
improvement in IOP following surgery, relying on 
standard surgical interventions such as AGV or 
trabeculectomy may be necessary. Despite variability in 
IOP outcomes, there was a significant decrease in 
reliance on IOP lowering medications in all patients. 
Finally, combined phacoemulsification and ECP may 
serve as an additional treatment measure in patients 
with moderate/advanced POAG who have already 
undergone trabeculectomies or AGV and still need 
additional intervention. Combined phacoemulsification 
and ECP may also serve as a bridge in patients who have 
received maximum medical therapy but not interested in 
undergoing an invasive glaucoma surgery. 
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